The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls.

Jay A PanditJennifer M RadinDanielle ChiangEmily G SpencerJeff B PawelekMira DiwanLeila RoumaniMichael J Mina

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

This preliminary report suggests that rebound after clearance of test positivity or symptom resolution is higher than previously reported. However, notably we observed a similar rate of rebound in both the NPR treatment and control groups. Large studies with diverse participants and extended follow-up are needed to better understand the rebound phenomena.

Keyphrases

sars cov
coronavirus disease
single molecule
newly diagnosed
respiratory syndrome coronavirus
replacement therapy